venetoclax,rituximab,zanubrutinib,bendamustine
beigene,roche,abbvie
['zanubrutinib', 'sequoia', 'rituximab', 'bendamustine', 'cll', 'ritux']
day 5 #icml2023 oral presentation zanubrutinib (zanu) versus bendamustine + rituximab (br) in patients (pts) with treatment-na ve (tn) cll/sll: extended follow-up of the sequoia study
#cll 
Associate Professor,  Fred Hutch Cancer Center, U of Washington. CLL/Lymphoma. Targeted therapy/Cellular therapy (CAR-T, Transplant)